Yıl: 2022 Cilt: 54 Sayı: 1 Sayfa Aralığı: 54 - 60 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2022.21288 İndeks Tarihi: 24-06-2022

Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats

Öz:
Objective: There might be dopaminergic connections between the retina and the brain. In this context, the study was aimed to investigate the possible interaction between the retina and basal ganglia through the dopaminergic system. Materials and Methods: In total, 32 healthy rats were randomized into 4 groups: healthy, Sham, dopamine antagonist injected group (risperidone, 0.04 mg/kg intravitreally), and dopamine agonist injected group (apomorphine, 0.4 mg/kg intravitreally). The locomotor activity and Morris water maze tests were applied to all rats twice, before the injection and 28 days after, to detect changes in movement, memory, and attention. Histopathologically, the basal ganglia and hippocampus regions were removed and examined. Results: In the locomotor activity test, a statistical significance was found between the first and last measurement values of the apomorphine group and a decrease in activities and an increase in resting times (P < .05). In the Morris water maze test, a statistical significance was detected between the first and last tests of the control group and the apomorphine groups and showed significantly shorter learning times (P < .05). Histological analyses of the substantia nigra and hippocampus were noteworthy in that the number of damaged neurons in the risperidone group was considerably higher than the other groups. The number of damaged neurons in the apomorphine group was significantly lower than in the healthy group. Conclusion: Intravitreal administration of dopamine agonists and antagonists has given rise to alterations in the cerebral dopaminergic system, leading to changes in locomotor activity and memory and histopathological changes.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Hunger L, Kumar A, Schmidt R. Abundance compensates kinetics: similar effect of dopamine signals on D1 and D2 receptor populations. J Neurosci. 2020;40(14):2868-2881. [CrossRef]
  • 2. Dziedzicka-Wasylewska M. Brain dopamine receptors--research perspectives and potential sites of regulation. Pol J Pharmacol. 2004;56(6):659-671.
  • 3. Mohana Devi S, Mahalaxmi I, Aswathy NP, Dhivya V, Balachandar V. Does retina play a role in Parkinson’s disease? Acta Neurol Belg. 2020;120(2):257-265. [CrossRef]
  • 4. Berke JD. What does dopamine mean? Nat Neurosci. 2018;21(6):787-793. [CrossRef]
  • 5. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108(1):17-40. [CrossRef]
  • 6. Martucci A, Cesareo M, Pinazo-Durán MD, et al. Is there a relationship between dopamine and rhegmatogenous retinal detachment? Neural Regen Res. 2020;15(2):311-314. [CrossRef]
  • 7. Kemenyova P, Turcani P, Sutovsky S, Waczulikova I. Optical coherence tomography and its use in optical neuritis and multiple sclerosis. Bratisl Lek Listy. 2014;115(11):723-729. [CrossRef]
  • 8. Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s disease. Mov Disord. 2014;29(1):61-67. [CrossRef]
  • 9. Germann D, Kurylo N, Han F. Risperidone. Profiles Drug Subst Excip Relat Methodol. 2012;37:313- 361. [CrossRef]
  • 10. Li A, Guo H, Luo X, et al. Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons. FASEB J. 2006;20(8):1263-1265. [CrossRef]
  • 11. Arroyo-García LE, Vázquez-Roque RA, Díaz A, et al. The effects of non-selective dopamine receptor activation by apomorphine in the mouse hippocampus. Mol Neurobiol. 2018;55(11):8625-8636. [CrossRef]
  • 12. Donthamsetti PC, Winter N, Schönberger M, et al. Optical control of dopamine receptors using a photoswitchable tethered inverse agonist. J Am Chem Soc. 2017;139(51):18522-18535. [CrossRef]
  • 13. Calsolaro V, Antognoli R, Okoye C, Monzani F. The use of antipsychotic drugs for treating behavioral symptoms in Alzheimer’s disease. Front Pharmacol. 2019;10:1465. [CrossRef]
  • 14. Stevens RM, Gannon MA, Griffith MS, Bardgett ME. Delayed yet persistent effects of daily risperidone on activity in developing rats. Behav Pharmacol. 2016;27(5):460-469. [CrossRef]
  • 15. Mattingly BA, Gotsick JE, Marin C. Locomotor activity and stereotypy in rats following repeated apomorphine treatments at 1-, 3-, or 7-day intervals. Pharmacol Biochem Behav. 1988;31(4):871-875. [CrossRef]
  • 16. Poddar I, Callahan PM, Hernandez CM, et al. Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats. Pharmacol Biochem Behav. 2020;189:172853. [CrossRef]
  • 17. Bardgett ME, Crane C, Baltes Thompson EC, Cox B, Downnen T. The effects of amphetamine on working memory and locomotor activity in adult rats administered risperidone early in life. Behav Brain Res. 2019;362:64-70. [CrossRef]
  • 18. Ikram H, Zakir R, Haleem DJ. Effects of single administration of apomorphine on memory and monoamine metabolism: a dose related study. Pak J Pharm Sci. 2018;31(2):439-445.
APA KOÇAK M, ates o, Hacimuftuoglu A, ATEŞ İ, TEKİN E, Ceylan O, Okkay U (2022). Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. , 54 - 60. 10.5152/eurasianjmed.2022.21288
Chicago KOÇAK Mehmet Nuri,ates orhan,Hacimuftuoglu Ahmet,ATEŞ İREM,TEKİN Erdal,Ceylan Onur,Okkay Ufuk Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. (2022): 54 - 60. 10.5152/eurasianjmed.2022.21288
MLA KOÇAK Mehmet Nuri,ates orhan,Hacimuftuoglu Ahmet,ATEŞ İREM,TEKİN Erdal,Ceylan Onur,Okkay Ufuk Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. , 2022, ss.54 - 60. 10.5152/eurasianjmed.2022.21288
AMA KOÇAK M,ates o,Hacimuftuoglu A,ATEŞ İ,TEKİN E,Ceylan O,Okkay U Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. . 2022; 54 - 60. 10.5152/eurasianjmed.2022.21288
Vancouver KOÇAK M,ates o,Hacimuftuoglu A,ATEŞ İ,TEKİN E,Ceylan O,Okkay U Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. . 2022; 54 - 60. 10.5152/eurasianjmed.2022.21288
IEEE KOÇAK M,ates o,Hacimuftuoglu A,ATEŞ İ,TEKİN E,Ceylan O,Okkay U "Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats." , ss.54 - 60, 2022. 10.5152/eurasianjmed.2022.21288
ISNAD KOÇAK, Mehmet Nuri vd. "Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats". (2022), 54-60. https://doi.org/10.5152/eurasianjmed.2022.21288
APA KOÇAK M, ates o, Hacimuftuoglu A, ATEŞ İ, TEKİN E, Ceylan O, Okkay U (2022). Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. Eurasian Journal of Medicine, 54(1), 54 - 60. 10.5152/eurasianjmed.2022.21288
Chicago KOÇAK Mehmet Nuri,ates orhan,Hacimuftuoglu Ahmet,ATEŞ İREM,TEKİN Erdal,Ceylan Onur,Okkay Ufuk Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. Eurasian Journal of Medicine 54, no.1 (2022): 54 - 60. 10.5152/eurasianjmed.2022.21288
MLA KOÇAK Mehmet Nuri,ates orhan,Hacimuftuoglu Ahmet,ATEŞ İREM,TEKİN Erdal,Ceylan Onur,Okkay Ufuk Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. Eurasian Journal of Medicine, vol.54, no.1, 2022, ss.54 - 60. 10.5152/eurasianjmed.2022.21288
AMA KOÇAK M,ates o,Hacimuftuoglu A,ATEŞ İ,TEKİN E,Ceylan O,Okkay U Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. Eurasian Journal of Medicine. 2022; 54(1): 54 - 60. 10.5152/eurasianjmed.2022.21288
Vancouver KOÇAK M,ates o,Hacimuftuoglu A,ATEŞ İ,TEKİN E,Ceylan O,Okkay U Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats. Eurasian Journal of Medicine. 2022; 54(1): 54 - 60. 10.5152/eurasianjmed.2022.21288
IEEE KOÇAK M,ates o,Hacimuftuoglu A,ATEŞ İ,TEKİN E,Ceylan O,Okkay U "Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats." Eurasian Journal of Medicine, 54, ss.54 - 60, 2022. 10.5152/eurasianjmed.2022.21288
ISNAD KOÇAK, Mehmet Nuri vd. "Does Intravitreal Dopamine Agonist and Antagonist Administration Have Effects on the Brain? An Experimental Study in Rats". Eurasian Journal of Medicine 54/1 (2022), 54-60. https://doi.org/10.5152/eurasianjmed.2022.21288